Endurant Capital Management LP Adverum Biotechnologies, Inc. Transaction History

Endurant Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$7.98 - $16.32 $1.71 Million - $3.51 Million	-214,823 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$5.12 - $12.22 $1.1 Million - $2.63 Million	214,823 New	214,823 $2.48 Million
Q3 2019 Nov 14, 2019	SELL	$5.24 - $15.89 $166,993 - $506,398	-31,869 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$5.1 - $11.89 $162,531 - $378,922	31,869 New	31,869 $379,000
Q4 2018 Feb 14, 2019	SELL	$2.87 - $5.92 $484,570 - $999,532	-168,840 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$4.5 - $7.6 $759,780 - $1.28 Million	168,840 New	168,840 $1.02 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $464M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.